Metabolic syndrome is a risk factor
for cardiovascular disease (CVD) and premature death, especially
in people with severe mental illness, such as schizophrenia.
Metabolic risk factors are partially attributable to unhealthy
lifestyle, including poor diet and lack of regular physical activity,
as well as side effects of antipsychotic medications [1−3]. Women
diagnosed with schizophrenia and treated with antipsychotic medications constitute a specific subgroup of the population with
higher risk for developing metabolic syndrome, and therefore they
should be routinely screened and treated for metabolic risk factors.
In this pilot study, we investigated the metabolic risk factors
among hospitalized women treated for schizophrenia
Source:
European Neuropsychopharmacology, 2013, 23, S467-S468
TY - JOUR
AU - Batinić, Borjanka
AU - Đerić-Jeremić, M.
AU - Duisin, Dragana
AU - Opačić, Goran
PY - 2013
UR - http://reff.f.bg.ac.rs/handle/123456789/1705
AB - Metabolic syndrome is a risk factor
for cardiovascular disease (CVD) and premature death, especially
in people with severe mental illness, such as schizophrenia.
Metabolic risk factors are partially attributable to unhealthy
lifestyle, including poor diet and lack of regular physical activity,
as well as side effects of antipsychotic medications [1−3]. Women
diagnosed with schizophrenia and treated with antipsychotic medications constitute a specific subgroup of the population with
higher risk for developing metabolic syndrome, and therefore they
should be routinely screened and treated for metabolic risk factors.
In this pilot study, we investigated the metabolic risk factors
among hospitalized women treated for schizophrenia
PB - Elsevier Science BV, Amsterdam
T2 - European Neuropsychopharmacology
T1 - Screening for metabolic risk factors in women treated for schizophrenia
EP - S468
SP - S467
VL - 23
DO - 10.1016/S0924-977X(13)70740-5
ER -
@article{
author = "Batinić, Borjanka and Đerić-Jeremić, M. and Duisin, Dragana and Opačić, Goran",
year = "2013",
abstract = "Metabolic syndrome is a risk factor
for cardiovascular disease (CVD) and premature death, especially
in people with severe mental illness, such as schizophrenia.
Metabolic risk factors are partially attributable to unhealthy
lifestyle, including poor diet and lack of regular physical activity,
as well as side effects of antipsychotic medications [1−3]. Women
diagnosed with schizophrenia and treated with antipsychotic medications constitute a specific subgroup of the population with
higher risk for developing metabolic syndrome, and therefore they
should be routinely screened and treated for metabolic risk factors.
In this pilot study, we investigated the metabolic risk factors
among hospitalized women treated for schizophrenia",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Screening for metabolic risk factors in women treated for schizophrenia",
pages = "S468-S467",
volume = "23",
doi = "10.1016/S0924-977X(13)70740-5"
}
Batinić, B., Đerić-Jeremić, M., Duisin, D.,& Opačić, G.. (2013). Screening for metabolic risk factors in women treated for schizophrenia. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 23, S467-S468.
https://doi.org/10.1016/S0924-977X(13)70740-5
Batinić B, Đerić-Jeremić M, Duisin D, Opačić G. Screening for metabolic risk factors in women treated for schizophrenia. in European Neuropsychopharmacology. 2013;23:S467-S468.
doi:10.1016/S0924-977X(13)70740-5 .
Batinić, Borjanka, Đerić-Jeremić, M., Duisin, Dragana, Opačić, Goran, "Screening for metabolic risk factors in women treated for schizophrenia" in European Neuropsychopharmacology, 23 (2013):S467-S468,
https://doi.org/10.1016/S0924-977X(13)70740-5 . .
